CN101039672A - 化合物 - Google Patents

化合物 Download PDF

Info

Publication number
CN101039672A
CN101039672A CNA2005800351651A CN200580035165A CN101039672A CN 101039672 A CN101039672 A CN 101039672A CN A2005800351651 A CNA2005800351651 A CN A2005800351651A CN 200580035165 A CN200580035165 A CN 200580035165A CN 101039672 A CN101039672 A CN 101039672A
Authority
CN
China
Prior art keywords
methyl
tetrahydro
benzimidazol
het
quinolinamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800351651A
Other languages
English (en)
Chinese (zh)
Inventor
K·古德蒙森
P·R·塞巴哈
L·D·理查森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of CN101039672A publication Critical patent/CN101039672A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA2005800351651A 2004-08-16 2005-08-12 化合物 Pending CN101039672A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60192804P 2004-08-16 2004-08-16
US60/601,928 2004-08-16

Publications (1)

Publication Number Publication Date
CN101039672A true CN101039672A (zh) 2007-09-19

Family

ID=35968075

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800351651A Pending CN101039672A (zh) 2004-08-16 2005-08-12 化合物

Country Status (18)

Country Link
US (1) US20080045537A1 (https=)
EP (1) EP1789045A2 (https=)
JP (1) JP2008510006A (https=)
KR (1) KR20070042568A (https=)
CN (1) CN101039672A (https=)
AR (1) AR050522A1 (https=)
AU (1) AU2005277638A1 (https=)
BR (1) BRPI0514438A (https=)
CA (1) CA2577100A1 (https=)
IL (1) IL181160A0 (https=)
MA (1) MA28814B1 (https=)
MX (1) MX2007001958A (https=)
NO (1) NO20071161L (https=)
PE (1) PE20060646A1 (https=)
RU (1) RU2350604C2 (https=)
TW (1) TW200619217A (https=)
WO (1) WO2006023400A2 (https=)
ZA (1) ZA200701282B (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102020993A (zh) * 2009-09-16 2011-04-20 Jsr株式会社 液晶取向剂、液晶取向膜、液晶显示元件、聚酰胺酸以及化合物
CN102051186A (zh) * 2009-10-28 2011-05-11 Jsr株式会社 液晶取向剂、液晶显示元件、聚酰胺酸、聚酰亚胺和化合物
CN102675305A (zh) * 2011-03-08 2012-09-19 中国科学院上海药物研究所 一类咪唑并吡啶类化合物及其制备方法和用途
CN103570683A (zh) * 2012-07-30 2014-02-12 中国科学院上海药物研究所 多取代胺类化合物及其制备方法和用途

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7728026B2 (en) 2005-04-11 2010-06-01 Abbott Laboratories, Inc. 2-substituted-1 h-benzimidazile-4-carboxamides are PARP inhibitors
PT1942108E (pt) 2005-10-28 2013-10-24 Ono Pharmaceutical Co Composto com um grupo básico e a sua utilização
WO2007058322A1 (ja) 2005-11-18 2007-05-24 Ono Pharmaceutical Co., Ltd. 塩基性基を含有する化合物およびその用途
EP2042503B1 (en) 2006-05-16 2013-01-30 Ono Pharmaceutical Co., Ltd. Compound having acidic group which may be protected, and use thereof
WO2008016006A1 (fr) 2006-07-31 2008-02-07 Ono Pharmaceutical Co., Ltd. Composé auquel un groupe cyclique est lié par une liaison spiro et son utilisation
GB0702695D0 (en) * 2007-02-12 2007-03-21 Ark Therapeutics Ltd Production of vectors
AR066162A1 (es) * 2007-07-31 2009-07-29 Bayer Cropscience Sa Derivados fungicidas de n- cicloalquil -n- carboxamida- biciclica
US20100222381A1 (en) 2009-02-27 2010-09-02 Hariprasad Vankayalapati Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors
JP5719028B2 (ja) 2010-10-06 2015-05-13 グラクソスミスクライン エルエルシー Ｐｉ３キナーゼ阻害剤としてのベンズイミダゾール誘導体
CN109069426B (zh) 2015-12-14 2021-10-29 X4 制药有限公司 治疗癌症的方法
WO2017106332A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
PL3393468T3 (pl) 2015-12-22 2023-01-23 X4 Pharmaceuticals, Inc. Metody leczenia niedoboru odporności
US11337969B2 (en) 2016-04-08 2022-05-24 X4 Pharmaceuticals, Inc. Methods for treating cancer
CN109640988A (zh) 2016-06-21 2019-04-16 X4 制药有限公司 Cxcr4抑制剂及其用途
WO2017223243A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
ES2870920T3 (es) 2016-06-21 2021-10-28 X4 Pharmaceuticals Inc Inhibidores de CXCR4 y usos de los mismos
EP3585387A4 (en) 2017-02-21 2020-08-12 Emory University CHEMIOKIN CXCR4 RECEIVER MODULATORS AND THEIR USES
JP7282786B2 (ja) * 2017-09-25 2023-05-29 シージーンテック （スーチョウ， チャイナ） カンパニー リミテッド Ｃｘｃｒ４阻害剤としてのヘテロアリール化合物、それを用いた組成物及び方法
KR102678977B1 (ko) * 2017-09-25 2024-06-28 씨젠테크 (쑤저우, 차이나) 컴퍼니 리미티드 Cxcr4 저해제로서 헤테로아릴 화합물, 그 조성물 및 이용 방법
US11649235B2 (en) 2018-03-19 2023-05-16 Emory University Pan-tropic entry inhibitors
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
CA3171250A1 (en) 2020-03-10 2021-09-16 E. Lynne KELLEY Methods for treating neutropenia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004512336A (ja) * 2000-09-15 2004-04-22 アノーメッド　インコーポレイティド ケモカインレセプター結合複素環式化合物
PT1317451E (pt) * 2000-09-15 2006-12-29 Anormed Inc Compostos heterocíclicos que se ligam a receptores de quimioquinas
US6835731B2 (en) * 2000-09-15 2004-12-28 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
CA2419224A1 (en) * 2000-09-15 2002-03-21 Anormed Inc. Chemokine receptor binding heterocyclic compounds
CA2467718C (en) * 2001-12-21 2011-04-26 Anormed Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
CN1930127B (zh) * 2004-03-15 2012-11-21 阿诺麦德股份有限公司 用于合成cxcr4拮抗剂的方法

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102020993A (zh) * 2009-09-16 2011-04-20 Jsr株式会社 液晶取向剂、液晶取向膜、液晶显示元件、聚酰胺酸以及化合物
CN102020993B (zh) * 2009-09-16 2014-10-29 Jsr株式会社 液晶取向剂、液晶取向膜、液晶显示元件、聚酰胺酸以及化合物
TWI477534B (zh) * 2009-09-16 2015-03-21 Jsr Corp 液晶配向劑、液晶配向膜、液晶顯示元件、聚醯胺酸及化合物
CN102051186A (zh) * 2009-10-28 2011-05-11 Jsr株式会社 液晶取向剂、液晶显示元件、聚酰胺酸、聚酰亚胺和化合物
CN102675305A (zh) * 2011-03-08 2012-09-19 中国科学院上海药物研究所 一类咪唑并吡啶类化合物及其制备方法和用途
CN102675305B (zh) * 2011-03-08 2014-11-12 中国科学院上海药物研究所 一类咪唑并吡啶类化合物及其制备方法和用途
CN103570683A (zh) * 2012-07-30 2014-02-12 中国科学院上海药物研究所 多取代胺类化合物及其制备方法和用途
CN103570683B (zh) * 2012-07-30 2018-04-17 中国科学院上海药物研究所 多取代胺类化合物及其制备方法和用途

Also Published As

Publication number Publication date
JP2008510006A (ja) 2008-04-03
US20080045537A1 (en) 2008-02-21
TW200619217A (en) 2006-06-16
IL181160A0 (en) 2007-07-04
EP1789045A2 (en) 2007-05-30
MX2007001958A (es) 2007-05-09
CA2577100A1 (en) 2006-03-02
RU2007105823A (ru) 2008-09-27
PE20060646A1 (es) 2006-08-04
AU2005277638A1 (en) 2006-03-02
WO2006023400A2 (en) 2006-03-02
AR050522A1 (es) 2006-11-01
ZA200701282B (en) 2010-05-26
KR20070042568A (ko) 2007-04-23
WO2006023400A3 (en) 2006-06-08
RU2350604C2 (ru) 2009-03-27
NO20071161L (no) 2007-05-14
BRPI0514438A (pt) 2008-06-10
MA28814B1 (fr) 2007-08-01

Similar Documents

Publication Publication Date Title
CN101039672A (zh) 化合物
CN100338044C (zh) Hiv蛋白酶抑制剂、含有它们的组合物、其药物应用及其合成原料
CN1149196C (zh) 作为血管紧张肽和内皮肽受体双重拮抗剂的联苯基磺酰胺
CN1058710C (zh) 苯甲酰胺衍生物及其制法、用途和含其的药物组合物
CN1280291C (zh) 用作磷酸二酯酶抑制剂的取代的吡咯并吡啶酮衍生物
CN1046724C (zh) 吡唑并吡啶化合物、含有它们的药物组合物、及其制法与用途
CN1483024A (zh) Vla-4抑制剂
CN1351601A (zh) 结合趋化因子受体的杂环化合物
CN1468217A (zh) 脂肪族含氮五员环化合物
CN1930160A (zh) Hiv整合酶抑制剂
CN1976915A (zh) Hiv整合酶抑制剂
CN1929737A (zh) Hiv整合酶抑制剂
CN1499972A (zh) 用作促肾上腺皮质激素释放因子抑制剂的咪唑基衍生物
CN1816551A (zh) 吡咯并嘧啶A2b选择性拮抗剂化合物,它们的合成及用途
CN1802375A (zh) 用于治疗炎性疾病的β－咔啉
CN1771231A (zh) 钙受体调节性化合物及其用途
CN1930146A (zh) 哌啶基羰基－吡咯烷和它们作为黑皮质素激动剂的用途
CN1068327C (zh) 2,7－取代的八氢－1H－吡啶并[1,2－a]吡嗪衍生物
CN1993358A (zh) 作为趋化因子受体拮抗剂的噻唑衍生物
CN1745071A (zh) 新型乙二胺衍生物
CN1735613A (zh) 稠合杂环化合物
CN1225637A (zh) 吡咯并三嗪和嘧啶化合物
CN100345853C (zh) 吡唑并嘧啶化合物及其制备方法
CN1870896A (zh) 用作hiv整合酶抑制剂的羟基吡啶并吡咯并吡嗪二酮化合物
CN1826340A (zh) 作为糖原磷酸化酶抑制剂的吡咯并吡啶－2－甲酸酰胺

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20070919